Proteomic kinetic analysis of blister fluid and serum in a patient with drug-induced toxic epidermal necrolysis. A comparison with skin immunohistochemistry.
[en] Drug-induced toxic epidermal necrolysis (TEN) is a rare but potentially lethal bullous disease whose complex pathomechanisms remain uncertain. The aim of the study was an exploratory attempt to assess TEN pathobiology using a combination of immunohistochemistry and proteomics. Skin blister fluid (BF) and serum were collected in a patient in the early TEN stage at day (D) +4 of evolution and three days later (D +7). Intravenous cyclosporine A (CsA) treatment was initiated since D +4. Immunohistochemistry was performed on skin blister biopsies. In addition, proteomic analyses compared the BF protein content before and at the issue of the 3-day CsA treatment. Proteins were selected according to their prominent differential abundance in BF between D+4 and D+7, when influenced by lesional skin cells, but not in serum. Among 300 proteins, four were considered. Glutathione transferase pi was related to oxidative stress in TEN epidermis. The monocyte differentiation antigen CD14 and myeloperoxidase indicated macrophage activation. The proinflammatory S100-A8 protein probably originated from activated keratinocytes and/or macrophages. These proteomic findings were in line with immunohistochemistry and supported the prominent involvement of keratinocytes and macrophages in TEN pathomechanism. As opposed to CD14, other proteins were mainly present in BF at D+7, confirming that CsA expressed little effect, if any, on the activity of keratinocytes and macrophages in the present TEN patient. Of note, the present exploratory study using proteomic analyses in a single TEN case supports a pathogenic hypothesis without establishing any firm conclusion.
Disciplines :
Dermatology
Author, co-author :
Paquet, Philippe
Meuwis, Marie-Alice ; Centre Hospitalier Universitaire de Liège - CHU > Gastro-Entérologie-Hépatologie
Mazzucchelli, Gabriel ; Université de Liège - ULiège > Center for Analytical Research and Technology (CART)
Delvenne, Philippe ; Université de Liège - ULiège > Département des sciences biomédicales et précliniques > Anatomie et cytologie pathologiques
PIERARD, Gérald ; Centre Hospitalier Universitaire de Liège - CHU > Dermatopathologie
Language :
English
Title :
Proteomic kinetic analysis of blister fluid and serum in a patient with drug-induced toxic epidermal necrolysis. A comparison with skin immunohistochemistry.
Paquet P, Piérard GE. New insights in toxic epidermal necrolysis (Lyell's syndrome). Clinical considérations, pathobiology and targeted treatments revisited. Drug Saf 2010; 33: 189-212.
Downey A, Jackson C, Harun N, et al. Toxic epidermal necrolysis: review of pathogenesis and management. J Am Acad Dermatol 2012; 66(6): 995-1003.
Le Cleach L, Delaire S, Boumsell L, et al. Blister fluid T lymphocytes during toxic epidermal necrolysis are functional cytotoxic cells which express human natural killer (NK) inhibitory receptors. Clin Exp Immunol 2000; 119: 225-230.
Chung WH, Hung SI, Yang JY, et al. Granulysin is a key médiator for disseminated keratinocyte death in Stevens-Johnson syndrome and toxic epidermal necrolysis. Nat Med 2008; 12: 1343-1350.
Paquet P, Nikkels A, Arrese JE, et al. Macrophages and tumor necrosis factor-alpha in toxic epidermal necrolysis. Arch Dermatol 1994; 130: 605-608.
Paquet P, Quatresooz P, Piérard GE. Factor XIIIa-positive dendrocytes in drug-induced toxic epidermal necrolysis (Lyell's syndrome). Paradoxical activation in the skin and raréfaction in lymph nodes. Dermatology 2003; 206: 374-378.
Paquet P, De Groote D, Piérard GE. Functionally-active macrophage-derived myeloperoxidase in the skin of drug-induced toxic epidermal necrolysis. Dermatology 2010; 220: 201-207.
De Araujo E, Dessirier V, Laprée G, et al. Death ligand TRAIL, secreted by CD1a+ and CD14+ cells in blister fluids, is involved in killing keratinocytes in toxic epidermal necrolysis. Exp Dermatol 2011; 20: 107-112.
Tohyama M, Watanabe H, Murakami S, et al. Possible involvement of CD16+ monocyte lineage cells in teh epidermal damage of Stevens-Johnson syndrome and toxic epidermal necrolysis. Br J Dermatol 2012; 166(2): 322-330
Paquet P, Piérard GE. Toxic epidermal necrolysis: revisiting the tentative link between early apoptosis and late necrosis. Int J Mol Med 2007; 19: 3-10.
Piérard GE, Paquet P. Facing up to toxic epidermal necrolysis. Expert Opin Pharmacother 2010; 11: 2443-2446.
Macdonald N, Cumberbatch M, Singh M, et al. Proteomic analysis of suction blister fluid isolated from human skin. Clin Exp Dermatol 2006; 31: 445-448.
Kool J, Reubsaet L, Wesseldijk F, et al. Suction blister fluid as potential body fluid for biomarker proteins. Proteomics 2007; 7: 3638-3650.
Bastuji-Garin S, Rzany B, Stern RS, et al. Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome and erythema multiforme. Arch Dermatol 1993; 129: 92-96.
Sassolas B, Haddad C, Mockenhaupt M, et al. ALDEN, an algorithm for assessment of drug causality in Stevens-Johnson syndrome and toxic epidermal necrolysis: comparison with case-control analysis. Clin Pharmacol Ther 2010; 88: 60-68.
Paquet P, Paquet F, Al Saleh W, et al. Immunoregulatory effectors in drug-induced toxic epidermal necrolysis. Am J Dermatopathol 2000; 22: 413-417.
Turtoi A, Mazzucchelli G, De Pauw E. Isotope coded protein label quantification of serum proteins--comparison with the label-free LC-MS and validation using the MRM approach. Talanta 2010; 80: 1487-1495.
Paquet P, Piérard GE. Glutathione-S-transferase n expression in toxic epidermal necrolysis: a marker of putative oxidative stress in keratinocytes. Skin Pharmacol Physiol 2007; 30: 66-70.
Leung TF, Tang NL, Wong GW, et al. CD 14 and Toll-like receptors: potential contribution of genetic factors and mechanisms to inflammation and allergy. Curr Drug Targets Inflamm Allergy 2005; 4: 169-175.
Da Silva Correia J, Soldau K, Christen U, et al. Lipopolysaccharide is in close proximity to each of the proteins in its membrane receptor complex transfer from CD14 to TLR4 and MD-2. J Biol Chem 2001; 276: 21129-21135.
Schutt C. CD14. Int J Biochem Cell Biol 1999; 31: 545-549.
Butler P, Stiegler G, Schuchmann M, et al. Soluble lipopolysaccharide receptor (CD14) is released via two different mechanisms from human monocytes and CD14 transfectants. Eur J Immunol 1995; 25: 604-610.
Frey EA, Miller DS, Jahr TG, et al. Soluble CD14 participates in the response of cells to lipopolysaccharide. J Exp Med 1992; 176: 1665-1671.
Schauber J, Dorschner RA, Coda AB, et al. Injury enhances TLR2 function and antimicrobial peptide expression through a vitamin D-dependent mechanism. J Clin Invest 2007; 117: 803-811.
Klechevsky E, Morita R, Liu M, et al. Functional specializations of human epidermal Langerhans cells and CD14+ dermal dendritic cells. Immunity 2008; 20: 497-510.
Rosenberger S, Thorey IS, Werner S, et al. A novel regulator of telomerase. S100A8 mediates differentiation-dependent and calcium-induced inhibition of telomerase activity in the human epidermal line HaCaT. J Biol Chem 2007; 282: 6126-6135.